Mononuclear Rare-Earth Metalloligands Exploiting a Divergent Ligand

Rare-earth tris-diketonato [RE(dike)3pyterpy] metalloligands can be prepared reacting at room temperature [RE(dike)3dme] (dme = 1,2-dimethoxyethane; dike = tta with Htta = 2-thenoyltrifluoroacetone and RE = La, 1; Y, 2; Eu, 3; Dy, 4; or dike = hfac with Hhfac hexafluoroacetylacetone, and RE = Eu, 5; Tb, 6; Yb 7) with 4'-(4‴-pyridil)-2,2':6',2″-terpyridine (pyterpy). The molecular structures of 1, 5, 6, and 7 have been studied through single-crystal X-ray diffraction showing mononuclear neutral complexes with the rare-earth ion in coordination number nine and with a muffin-like coordination geometry. [RE(tta)3pyterpy] promptly reacts with [M(tta)2dme] with formation of [Mpyterpy2][RE(tta)4]2 (M = Zn, RE = Y, 8; M = Co, RE = Dy, 9). Consistently, [Zn(hfac)2dme] reacts at room temperature with 2 equiv of pyterpy yielding [Znpyterpy2][hfac]2 10 that easily can be transformed by reaction with 2 equiv of [Eu(hfac)3] in [Znpyterpy2][Eu(hfac)4]2 11 that has been structurally characterized. Finally, 1, 2, 3, 5, and 7 metalloligands react at room temperature in few minutes with [PtCl(μ-Cl)PPh3]2 yielding the heterometallic molecular complexes [RE(dike)3pyterpyPtCl2PPh3] (dike = tta, RE = La, 12; Y, 13; Eu; 14; dike = hfac, RE = Eu, 15; Yb, 16).

trans-Dichloro(triphenylarsino)(N,N-dialkylamino)platinum(II) Complexes: In Search of New Scaffolds to Circumvent Cisplatin Resistance

The high incidence of the resistance phenomenon represents one of the most important limitations to the clinical usefulness of cisplatin as an anticancer drug. Notwithstanding the considerable efforts to solve this problem, the circumvention of cisplatin resistance remains a challenge in the treatment of cancer. In this work, the synthesis and characterization of two trans-dichloro(triphenylarsino)(N,N-dialkylamino)platinum(II) complexes (1 and 2) were described. The trypan blue exclusion assay demonstrated an interesting antiproliferative effect for complex 1 in ovarian carcinoma-resistant cells, A2780cis. Quantitative analysis performed by ICP-AES demonstrated a scarce ability to platinate DNA, and a significant intracellular accumulation. The investigation of the mechanism of action highlighted the ability of 1 to inhibit the relaxation of supercoiled plasmid DNA mediated by topoisomerase II and to stabilize the cleavable complex. Cytofluorimetric analyses indicated the activation of the apoptotic pathway and the mitochondrial membrane depolarization. Therefore, topoisomerase II and mitochondria could represent possible intracellular targets. The biological properties of 1 and 2 were compared to those of the related trans-dichloro(triphenylphosphino)(N,N-dialkylamino)platinum(II) complexes in order to draw structure–activity relationships useful to face the resistance phenotype.

New trans dichloro (triphenylphosphine)platinum(II) complexes containing N-(butyl),N-(arylmethyl)amino ligands: Synthesis, cytotoxicity and mechanism of action

Some new platinum(II) complexes have been prepared, of general formula trans-[PtCl2(PPh3){NH(Bu)CH2Ar}], where the dimension of the Ar residue in the secondary amines has been varied from small phenyl to large pyrenyl group. The obtained complexes, tested in vitro towards a panel of human tumor cell lines showed an interesting antiproliferative effect on both cisplatin-sensitive and -resistant cells. For the most cytotoxic derivative 2a the investigation on the mechanism of action highlighted the ability to induce apoptosis on resistant cells and interestingly, to inhibit the catalytic activity of topoisomerase II.